Cargando…

Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis

BACKGROUND: Physiologic determinants, such as pulse pressure [difference between systolic blood pressure (SBP) and diastolic BP (DBP)], mean arterial pressure (2/3 DBP + 1/3 SBP), and double product [beats per minute (bpm) × SBP], are linked to cardiovascular outcomes. The effects of canagliflozin,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pfeifer, Michael, Townsend, Raymond R., Davies, Michael J., Vijapurkar, Ujjwala, Ren, Jimmy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327537/ https://www.ncbi.nlm.nih.gov/pubmed/28241822 http://dx.doi.org/10.1186/s12933-017-0511-0

Ejemplares similares

Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials
por: Gilbert, Richard E., et al.
Publicado: (2017)

Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data
por: Davies, Michael J., et al.
Publicado: (2017)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
por: Davies, Michael J, et al.
Publicado: (2017)

A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures
por: Patel, Charmi A., et al.
Publicado: (2016)

Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin
por: Leiter, Lawrence A., et al.
Publicado: (2016)

Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis
por: Sinclair, Alan J., et al.
Publicado: (2016)

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus
por: Davies, M. J., et al.
Publicado: (2015)

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
por: Sinclair, Alan, et al.
Publicado: (2014)

Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus
por: Desai, Mehul, et al.
Publicado: (2017)

Mechanisms of action of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2022)

Benefits/Risks of Sodium–Glucose Co-Transporter 2 Inhibitor Canagliflozin in Women for the Treatment of Type 2 Diabetes
por: Kushner, Pamela
Publicado: (2016)

Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus()
por: Qiu, Rong, et al.
Publicado: (2014)

Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer’s Disease
por: Stanciu, Gabriela Dumitrita, et al.
Publicado: (2023)

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
por: Kelmenson, Daniel A., et al.
Publicado: (2017)

Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes
por: Sha, Sue, et al.
Publicado: (2014)

Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants
por: Devineni, Damayanthi, et al.
Publicado: (2015)

An Effective Sodium-Dependent Glucose Transporter 2 Inhibition, Canagliflozin, Prevents Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats
por: He, Lili, et al.
Publicado: (2022)

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
por: Forst, T, et al.
Publicado: (2014)

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
por: Woo, Vincent, et al.
Publicado: (2018)

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes
por: Polidori, David, et al.
Publicado: (2014)

Correction: Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes
Publicado: (2014)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
por: Triplitt, Curtis, et al.
Publicado: (2015)

A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus
por: Nardolillo, AnneMarie, et al.
Publicado: (2014)

Intra‐ and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin
por: Polidori, David, et al.
Publicado: (2018)

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
por: Rodbard, H. W., et al.
Publicado: (2016)

GMP Compliant Synthesis of [(18)F]Canagliflozin, a Novel PET Tracer for the Sodium–Glucose Cotransporter 2
por: van der Hoek, Sjoukje, et al.
Publicado: (2021)

An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes
por: Messana, Joseph A, et al.
Publicado: (2017)

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012)

Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes
por: Ueda, Tomoya, et al.
Publicado: (2021)

The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus
por: Evans, Marc, et al.
Publicado: (2022)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors
por: Wysham, Carol H., et al.
Publicado: (2017)

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
por: Yagi, Shusuke, et al.
Publicado: (2017)

The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia/Reperfusion Injury in Rats
por: Korkmaz-Icöz, Sevil, et al.
Publicado: (2021)

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
por: Haas, B, et al.
Publicado: (2014)

Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS)
por: Hassanein, Mohamed, et al.
Publicado: (2017)

Differential effect of canagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice
por: Otsuka, Hiroko, et al.
Publicado: (2022)

Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Kumar, Surender, et al.
Publicado: (2019)

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
por: Iijima, Hiroaki, et al.
Publicado: (2015)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India
por: Prasanna Kumar, K. M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_62btl750o4mg2nm488p41a08j3